Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.22.1
Research and Development Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 107 Months Ended
Aug. 31, 2021
Feb. 28, 2021
Nov. 30, 2019
Sep. 30, 2018
Jun. 30, 2017
Dec. 31, 2021
Jun. 30, 2021
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Nov. 30, 2019
Jun. 23, 2017
Research And Development Collaboration Agreements [Line Items]                        
Total research and development revenue                 $ 38,697 $ 15,635    
Common stock, shares issued           56,305,049     56,305,049 49,984,333    
Common stock, par value           $ 0.001     $ 0.001 $ 0.001    
Revenue from grant                 $ 38,697 $ 18,845    
Grant Agreements | Grants Revenue Receivable                        
Research And Development Collaboration Agreements [Line Items]                        
Reimbursement amounts submitted in excess of amounts received are recorded as receivables           $ 0     0 0    
Grant                        
Research And Development Collaboration Agreements [Line Items]                        
Revenue from grant                 0 3,210    
Takeda Pharmaceuticals Inc                        
Research And Development Collaboration Agreements [Line Items]                        
Purchase price per share                       $ 6.8423
Deferred revenue, current           0     0 789    
Deferred revenue, non-current           0     0 3,106    
Cancer Prevention and Research Institute of Texas | CPRIT Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Product development grant awarded       $ 15,200                
Cancer Prevention and Research Institute of Texas | ETB MT-3724 | CPRIT Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Aggregate proceeds received from award granted                     $ 10,600  
Revenue from grant                 20,000      
Grants Receivable           0     0      
Takeda Development Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Total transaction price                 29,800      
Upfront payment                 30,000      
Development milestone payment that is achievable               $ 10,000        
Expected co-share payments payable           10,200     10,200      
Total research and development revenue             $ 12,900          
Deferred revenue           0     0 1,300    
Takeda Development Agreement | Maximum                        
Research And Development Collaboration Agreements [Line Items]                        
Clinical and regulatory milestone payments $ 22,250                      
Takeda Multi Target Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Upfront payment         $ 5,000              
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc                        
Research And Development Collaboration Agreements [Line Items]                        
Deferred revenue           2,600     2,600 2,600    
Cumulative payments received                 5,000      
Aggregate milestone payments upon exercise of option to license ETBS           30,000     30,000      
Milestone payments receivable if option is exercised                 397,000      
Takeda Multi Target Agreement | Maximum | Takeda Pharmaceuticals Inc                        
Research And Development Collaboration Agreements [Line Items]                        
Contractual contingency fees                 10,000      
Commercial milestone payment                 150,000      
Vertex Collaboration Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Upfront payment     $ 38,000                  
Total research and development revenue           14,600            
Deferred revenue           0     0 $ 18,400    
Milestone payments receivable if option is exercised     180,000                  
Upfront payment, cash     23,000                  
Upfront payment, equity method investments     $ 15,000               $ 15,000  
Common stock, shares issued     1,666,666               1,666,666  
Common stock, par value     $ 0.001               $ 0.001  
Vertex Collaboration Agreement | Common Stock                        
Research And Development Collaboration Agreements [Line Items]                        
Purchase price per share     $ 9.00               $ 9.00  
Fair value of allocated consideration     $ 4,500                  
Vertex Collaboration Agreement | Sales Milestone                        
Research And Development Collaboration Agreements [Line Items]                        
Milestone payments receivable if option is exercised     70,000                  
Vertex Collaboration Agreement | ETBs                        
Research And Development Collaboration Agreements [Line Items]                        
Aggregate milestone payments upon exercise of option to license ETBS     $ 22,000               $ 22,000  
Bristol Myers Squibb Collaboration Agreement                        
Research And Development Collaboration Agreements [Line Items]                        
Upfront payment   $ 70,000                    
Milestone payments receivable if option is exercised   874,500                    
Deferred revenue, current   32,800       32,800     32,800      
Deferred revenue, non-current   30,700       $ 30,700     $ 30,700      
Transaction price allocated to performance obligations   70,000                    
Bristol Myers Squibb Collaboration Agreement | Sales Milestone                        
Research And Development Collaboration Agreements [Line Items]                        
Milestone payments receivable if option is exercised   $ 450,000